Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

Serina Therapeutics, Inc.

2026-Q1 EPS reported -$0.58

Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.
Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.
SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.
Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Serina Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $6.9 million, EPS $(0.58) per basic and diluted share.

Period: the first quarter ended March 31, 2026
Net income: $6.9 million
EPS: $(0.58) per basic and diluted share
Result: reported results

Exact text from the filing

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.